UroGen Pharma (URGN) Capital Expenditures (2017 - 2026)
UroGen Pharma's (URGN) quarterly Capital Expenditures came in at $2.3 million in Q1 2026, up 1169.72% YoY from $183661.8 in Q1 2025, and up 245.93% on a QoQ basis from -$1.6 million in Q4 2025.
UroGen Pharma (URGN) Capital Expenditures (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Capital Expenditures data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Capital Expenditures rose 1169.72% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 1079.64% YoY) and the FY2025 annual result came in at $4.6 million, up 415.53% from the prior year.
- Capital Expenditures advanced to $2.3 million in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q3 2025 to a low of -$1.6 million in Q4 2025.
- A 5-year average of $354235.3 and a median of $169000.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 2066.34% in 2025, down 829.68% in 2025.
- Tracing URGN's Capital Expenditures over 5 years: stood at $269000.0 in 2022, then slumped by 104.46% to -$12000.0 in 2023, then jumped by 1925.0% to $219000.0 in 2024, then plunged by 829.68% to -$1.6 million in 2025, then soared by 245.93% to $2.3 million in 2026.
- The last three Capital Expenditures figures came in at $2.3 million (Q1 2026), -$1.6 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Jun 30, 2026 | 1.27 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 430,000.00 |
| Jun 30, 2025 | 430,000.00 |
| Mar 31, 2025 | -218,000.00 |
| Mar 31, 2025 | -218,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Dec 31, 2024 | 219,000.00 |
| Sep 30, 2024 | -303,000.00 |
| Sep 30, 2024 | -303,000.00 |
| Jun 30, 2024 | -425,000.00 |
| Jun 30, 2024 | -425,000.00 |
| Mar 31, 2024 | -940,000.00 |
| Mar 31, 2024 | -940,000.00 |